Advertisement
CABA vs FATE
Which Stock Would AI Choose? Cabaletta Bio (CABA) vs. Fate Therapeutics (FATE) Stock Comparison
Key Takeaways
- Both CABA and FATE are clinical-stage biotechnology companies pursuing cell therapies for autoimmune diseases, but they use different manufacturing platforms and lead programs.
- CABA (Cabaletta Bio) is advancing rese-cel, a CD19-targeted CAR T-cell therapy, with recent preclinical and clinical data across multiple autoimmune indications.
- FATE (Fate Therapeutics) is developing off-the-shelf, iPSC-derived cell therapies, with lead candidate FT819 progressing into Phase 2 trials for lupus nephritis.
- Recent momentum has diverged: CABA has pulled back in recent weeks after a strong run, while FATE has retained a larger year-to-date gain despite elevated volatility.
- Both names carry meaningful clinical, regulatory, and cash-burn risk typical of early-stage biotech, making relative performance and market positioning highly sentiment-driven.
- For more detail on each company's major news and today's price action, explore CABA Major News and CABA Today's Price Move, as well as FATE Major News and FATE Today's Price Move.
- To see how algorithmic strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating the emerging field of cell therapy for autoimmune disease often weigh multiple clinical-stage names side by side. Cabaletta Bio (CABA) and Fate Therapeutics (FATE) are two such companies, each pursuing engineered cell therapies but through distinct scientific and manufacturing approaches. This stock comparison is most relevant to traders and investors who follow biotechnology catalysts, clinical data readouts, and high-volatility small-cap equities. Because both firms remain pre-revenue and depend heavily on pipeline milestones, their share prices tend to react sharply to trial updates, financing events, and shifts in broader sector sentiment rather than to traditional earnings fundamentals.
CABA Overview and Recent Performance
Cabaletta Bio is a clinical-stage biotechnology company focused on engineered T-cell therapies for B cell–mediated autoimmune diseases. Its lead asset, rese-cel, is a CD19-directed CAR T-cell (chimeric antigen receptor T-cell) therapy designed to selectively deplete B cells that drive autoimmunity. In recent weeks, the company has presented data across its RESET clinical program, including preconditioning-free results and automated-manufacturing translational data, while also entering a multi-year commercial supply agreement to scale production. The company raised additional capital through an underwritten offering, reflecting both its funding needs and investor interest. After a strong upward move earlier in the year, CABA shares have consolidated and pulled back in recent market activity, a pattern consistent with profit-taking and elevated short interest following a data-driven rally.
FATE Overview and Recent Performance
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cell therapies. Its platform uses induced pluripotent stem cells (iPSCs) — engineered master cell lines that can be manufactured in advance and stored for on-demand use — to create CAR T-cell and CAR NK-cell product candidates for cancer and immune disorders. Its lead program, FT819, an off-the-shelf CD19-targeted CAR T-cell therapy, has advanced into a Phase 2 trial in lupus nephritis, with recent non-dilutive grant support and early clinical signals drawing attention. In recent weeks, FATE shares have shown pronounced volatility, trading below short-term moving averages at times even while retaining a substantial year-to-date gain. Sentiment has swung between optimism around pipeline progress and caution over clinical data interpretation and cash-burn concerns.
Trending AI Robots
For traders who prefer a data-driven approach to these fast-moving names, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and basket of securities. Because not every bot suits every market regime, only those best aligned with current market conditions are featured in the Trending AI Robots section, helping users surface the strategies most relevant right now. If you would like to see how AI-powered systems are currently positioning across the market, consider exploring the Trending AI Robots page.
Head-to-Head Comparison
The two companies differ most sharply in their technology and business models. CABA uses a patient-derived, autologous CAR T-cell approach, which can offer potent, potentially durable responses but typically involves more complex, individualized manufacturing. FATE uses an off-the-shelf iPSC platform designed to lower manufacturing cost and enable broader, on-demand patient access. In terms of growth drivers, CABA benefits from a wider autoimmune pipeline and manufacturing-scale partnerships, while FATE leans on platform scalability and oncology-plus-immunology optionality. On recent momentum, FATE has shown larger cumulative percentage gains over the year but with sharper drawdowns, whereas CABA has exhibited a steadier recent consolidation after its own rally. Both carry high cash-burn, single-asset concentration, and regulatory risk, so the trade-off for investors is largely between two different philosophies of cell therapy rather than between an established and an unproven business.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely view CABA as the comparatively more stable candidate in the current environment, given its broader clinical dataset, financing activity, and manufacturing agreements supporting a longer operational runway. However, FATE offers a differentiated platform with potentially greater upside optionality, balanced against higher volatility and a more concentrated near-term catalyst profile. The verdict is therefore probabilistic rather than definitive: the AI's preference may favor CABA on relative trend consistency, while acknowledging that FATE could outperform on the strength of its own clinical catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and FATE is a StrongBuy.
CABA's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CABA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FATE's RSI Indicator ascends from oversold territory
The RSI Oscillator for FATE moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 35 of the 37 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 86 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CABA | FATE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | 58 | |
P/E GROWTH RATING 1..100 | 9 | 13 | |
SEASONALITY SCORE 1..100 | 28 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FATE's Valuation (50) in the Biotechnology industry is in the same range as CABA (51) in the null industry. This means that FATE’s stock grew similarly to CABA’s over the last 12 months.
FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CABA (100) in the null industry. This means that FATE’s stock grew similarly to CABA’s over the last 12 months.
FATE's SMR Rating (98) in the Biotechnology industry is in the same range as CABA (98) in the null industry. This means that FATE’s stock grew similarly to CABA’s over the last 12 months.
FATE's Price Growth Rating (58) in the Biotechnology industry is in the same range as CABA (86) in the null industry. This means that FATE’s stock grew similarly to CABA’s over the last 12 months.
CABA's P/E Growth Rating (9) in the null industry is in the same range as FATE (13) in the Biotechnology industry. This means that CABA’s stock grew similarly to FATE’s over the last 12 months.
| CABA | FATE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 88% | 8 days ago 87% |
| Declines ODDS (%) | 9 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CABA’s FA Score shows that 1 FA rating(s) are green while FATE’s FA Score has 1 green FA rating(s).
- CABA’s FA Score: 1 green, 4 red.
- FATE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CABA’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).
- CABA’s TA Score: 5 bullish, 3 bearish.
- FATE’s TA Score: 4 bullish, 4 bearish.
Price Growth
CABA (@Biotechnology) experienced а +2.11% price change this week, while FATE (@Biotechnology) price change was -13.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CABA is expected to report earnings on Mar 18, 2027.
FATE is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CABA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with AURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then AURA could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -3.33% | ||
| AURA - CABA | 49% Loosely correlated | -0.13% | ||
| EDIT - CABA | 49% Loosely correlated | -8.91% | ||
| VIR - CABA | 47% Loosely correlated | -3.63% | ||
| NCEL - CABA | 47% Loosely correlated | +4.00% | ||
| FATE - CABA | 47% Loosely correlated | -8.76% | ||
More | ||||
FATE and
Correlation & Price change
A.I.dvisor indicates that over the last year, FATE has been loosely correlated with NKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then NKTX could also see price increases.
| Ticker / NAME | Correlation To FATE | 1D Price Change % | ||
|---|---|---|---|---|
| FATE | 100% | -8.76% | ||
| NKTX - FATE | 45% Loosely correlated | -15.09% | ||
| VCYT - FATE | 44% Loosely correlated | -7.18% | ||
| CABA - FATE | 43% Loosely correlated | -3.33% | ||
| SANA - FATE | 43% Loosely correlated | -1.42% | ||
| CYTK - FATE | 41% Loosely correlated | +1.89% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| APRT | 46.98 | 0.53 | +1.14% |
| AllianzIM U.S. Equity Buffer10 Apr ETF (APRT) | |||
| LQDH | 92.03 | 0.06 | +0.07% |
| iShares Interest Rate Hedged Corporate Bond ETF (LQDH) | |||
| SIMS | 45.70 | N/A | N/A |
| State Street SPDR S&P Kensho Intelligent Structures ETF (SIMS) | |||
| PSCI | 165.20 | -0.99 | -0.59% |
| Invesco S&P SmallCap Industrials ETF (PSCI) | |||
| ARKK | 77.10 | -1.88 | -2.38% |
| ARK Innovation ETF (ARKK) | |||